Tarek Ezzeddine, MD
Internal Medicine · Rancho Cucamonga, CANPI 1740471879
Payments from drug & device makers
What this record shows
AstraZeneca accounts for 70.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $1,349 and has fallen 90.7% since, to $125 in 2024.
Across 23 payments — averaging $74.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Melinta Therapeutics, LLC$250
- Sunovion Pharmaceuticals Inc.$106
- AbbVie$103
- Johnson & Johnson$22
- Boston Scientific$16
- plus $15 from 1 others
Across 63 payments — averaging $20,857 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$482K
- AstraZeneca$389K
- Bioxcel Therapeutics, Inc.$198K
- Janssen Research & Development, LLC$91K
- E.r. Squibb & Sons, L.L.C.$56K
- AbbVie$36K
- plus $61K from 4 others
What the payments were for
- Travel & lodging$96956%
- Food & beverage$75244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $1,208 |
| Melinta Therapeutics, LLC | 2 | $250 |
| Sunovion Pharmaceuticals Inc. | 7 | $106 |
| AbbVie | 1 | $103 |
| Johnson & Johnson | 1 | $22 |
| Boston Scientific | 1 | $16 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,720 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $18,578 |
| JanuviaSitagliptin Phosphate | 19 | $11,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,608 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $1,486 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $1,040 |
| Levothyroxine Sodium | 58 | $779 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $752 |
| Atorvastatin Calcium | 97 | $677 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $551 |
| Tamsulosin Hcl | 45 | $524 |
| Donepezil Hcl | 33 | $382 |
| Metformin Hcl | 64 | $380 |
| Losartan Potassium | 52 | $362 |
| Gabapentin | 40 | $345 |
| Fluoxetine Hcl | 14 | $297 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rancho Cucamonga
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.